229 related articles for article (PubMed ID: 35030332)
1. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
[TBL] [Abstract][Full Text] [Related]
3. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
4. Real-world implementation of non-endoscopic triage testing for Barrett's oesophagus during COVID-19.
Landy R; Killcoyne S; Tang C; Juniat S; O'Donovan M; Goel N; Gehrung M; Fitzgerald RC
QJM; 2023 Sep; 116(8):659-666. PubMed ID: 37220898
[TBL] [Abstract][Full Text] [Related]
5. A non-endoscopic device to sample the oesophageal microbiota: a case-control study.
Elliott DRF; Walker AW; O'Donovan M; Parkhill J; Fitzgerald RC
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):32-42. PubMed ID: 28404012
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic radiofrequency ablation or surveillance in patients with Barrett's oesophagus with confirmed low-grade dysplasia: a multicentre randomised trial.
Barret M; Pioche M; Terris B; Ponchon T; Cholet F; Zerbib F; Chabrun E; Le Rhun M; Coron E; Giovannini M; Caillol F; Laugier R; Jacques J; Legros R; Boustiere C; Rahmi G; Metivier-Cesbron E; Vanbiervliet G; Bauret P; Escourrou J; Branche J; Jilet L; Abdoul H; Kaddour N; Leblanc S; Bensoussan M; Prat F; Chaussade S
Gut; 2021 Jun; 70(6):1014-1022. PubMed ID: 33685969
[TBL] [Abstract][Full Text] [Related]
7. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
[TBL] [Abstract][Full Text] [Related]
8. Oesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation.
Chien S; Glen P; Penman I; Cruickshank N; Bryce G; Crumley A; Phull P; Miller M; Fletcher J; Gunjaca I; Apollos J; Robertson K; Fullarton G
Br J Surg; 2024 May; 111(5):. PubMed ID: 38736137
[TBL] [Abstract][Full Text] [Related]
9. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.
Chettouh H; Mowforth O; Galeano-Dalmau N; Bezawada N; Ross-Innes C; MacRae S; Debiram-Beecham I; O'Donovan M; Fitzgerald RC
Gut; 2018 Nov; 67(11):1942-1949. PubMed ID: 29084829
[TBL] [Abstract][Full Text] [Related]
10. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
12. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
13. Diagnosing dysplasia in Barrett's oesophagus still requires Seattle protocol biopsy in the era of modern video endoscopy: results from a tertiary centre Barrett's dysplasia database.
Nachiappan A; Ragunath K; Card T; Kaye P
Scand J Gastroenterol; 2020 Jan; 55(1):9-13. PubMed ID: 31880176
[No Abstract] [Full Text] [Related]
14. Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
Offman J; Muldrew B; O'Donovan M; Debiram-Beecham I; Pesola F; Kaimi I; Smith SG; Wilson A; Khan Z; Lao-Sirieix P; Aigret B; Walter FM; Rubin G; Morris S; Jackson C; Sasieni P; Fitzgerald RC;
BMC Cancer; 2018 Aug; 18(1):784. PubMed ID: 30075763
[TBL] [Abstract][Full Text] [Related]
15. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
16. Dedicated Barrett's surveillance sessions managed by trained endoscopists improve dysplasia detection rate.
Ooi J; Wilson P; Walker G; Blaker P; DeMartino S; O'Donohue J; Reffitt D; Lanaspre E; Chang F; Meenan J; Dunn JM
Endoscopy; 2017 Jun; 49(6):524-528. PubMed ID: 28399610
[No Abstract] [Full Text] [Related]
17. Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning.
Berman AG; Tan WK; O'Donovan M; Markowetz F; Fitzgerald RC
EBioMedicine; 2022 Aug; 82():104160. PubMed ID: 35843173
[TBL] [Abstract][Full Text] [Related]
18. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.
Cotton CC; Haidry R; Thrift AP; Lovat L; Shaheen NJ
Gastroenterology; 2018 Aug; 155(2):316-326.e6. PubMed ID: 29655833
[TBL] [Abstract][Full Text] [Related]
19. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus.
Larghi A; Lightdale CJ; Memeo L; Bhagat G; Okpara N; Rotterdam H
Gastrointest Endosc; 2005 Jul; 62(1):16-23. PubMed ID: 15990814
[TBL] [Abstract][Full Text] [Related]
20. Past, present and future of Barrett's oesophagus.
Tan WK; di Pietro M; Fitzgerald RC
Eur J Surg Oncol; 2017 Jul; 43(7):1148-1160. PubMed ID: 28256346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
